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survival data were extracted from a sample of members
enrolled in a large Health Maintenance Organization.
Study subjects were deﬁned as persons aged >40y who,
between 1995 and 2000, had at least 2 visits to a physi-
cian or one hospital admission with a diagnosis of COPD
and at least 90 days exposure to LABA and/or ICS. Cat-
egories of costs captured included medications, physician
visits, and hospitalizations. Survival was estimated using
a parametric regression model. Costs were adjusted for
censoring and known prognostic factors, including demo-
graphic variables and measures of disease severity. A cost-
effectiveness analysis was conducted from a third party
payer perspective over a time horizon of 36 months.
RESULTS: The estimated average survival and costs
were: 2.4 life years (LY) (CI: 2.3; 2.5) and $43,900 (95%
CI: $38,600; $51,800) for not receiving ICS or LABA; 2.7
LY (CI: 2.6; 2.8) and $36,750 (CI: $29,370; $43,800) 
for ICS alone; 2.7 LY (CI: 2.6; 2.8) and $44,900 (CI:
$38,700; $51,840) for LABA alone; and, 2.8 LY (CI: 2.7;
2.9) and $43,250 (CI: $36,530; $56,900) for subjects
treated with both ICS and LABA. The most favorable
treatment options were ICS and the combination ICS +
LABA. CONCLUSIONS: There is an acute need to ﬁnd
cost-effective treatments for persons with COPD. ICS and
LABA are currently being tested in randomized trials. 
If the impact on survival compares to that shown in
observational studies, those therapies are likely to be cost-
effective in the United States.
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OBJECTIVES: Lung transplant is increasingly becoming
the choice of therapy for several end-stage pulmonary
conditions. Factors critical to making decisions for a lung
transplant revolve around transplant costs and improve-
ments in health-related quality of life (HRQL) post-
transplant. The primary objectives of this study are: a) 
To compare the HRQL of transplant recipients versus
candidates; and b) To compare recipients versus candi-
dates on utilities derived using two methodologies by
Nichol et al. (2001) and Brazier et al. (2002).
METHODS: A survey questionnaire was mailed to 145
lung or heart-lung transplant recipients and 99 candidates
awaiting lung transplant at a major University hospital in
the Midwestern USA. The questionnaire comprised of
instruments such as the SF-36, Center for Epidemiologic
Studies Depression (CES-D) Scale, Symptom Distress
Scale (SDS), Illness Intrusion Rating Scale (IIRS), Pul-
monary Scale (PS), Dyspnea Scale (DS), and Health Status
(VAS). T-tests were employed to analyze differences
between the two groups on the HRQL measures.
RESULTS: There were a total of 166 respondents (99
recipients and 67 candidates). Recipients had signiﬁcantly
higher SF-36 PCS scores (39.97 vs. 25.56, p = 0.001) and
VAS scores (73.30 vs. 49.24, p = 0.001) as compared to
the candidates. No signiﬁcant differences were observed
between the 2 groups on the SF-36 MCS and CES-D
scores. Recipients demonstrated signiﬁcantly lower levels
of dyspnea, pulmonary distress, and illness intrusion in
comparison to transplant candidates. Both the method-
ologies for deriving utilities from the SF-36 yielded higher
scores for recipients versus the candidates; Nichol utili-
ties (0.76 vs. 0.69, p = 0.001) and Brazier utilities (0.70
vs. 0.63, p = 0.001). CONCLUSIONS: It was observed
that in general recipients had signiﬁcant improvements in
physical health as compared to candidates. The incre-
mental beneﬁt in terms of utilities would be larger when
calculated using the Nichol methodology, despite both
methodologies being based on the SF-36 and standard
gamble. Further research needs focus on the validity of
these utilities for purposes of a cost-utility analysis.
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HRQoL is an important outcome measure for chronic
childhood diseases. However, it is infrequently used in
Asia due to the difﬁculty of obtaining appropriately trans-
lated and culturally adapted instruments. We adapted the
Childhood Asthma Questionnaires C (CAQ-C) previ-
ously used in UK and Australia in children aged 11 to 16
years old. OBJECTIVES: To culturally adapt and validate
a disease speciﬁc HRQoL questionnaire, CAQ-C for
childhood asthma in Singapore. METHODS: CAQ-C
was adapted after pre-testing in asthmatic children.
Changes to the UK and Australia versions were made to
reﬂect the Singapore educational system, culture, lan-
guage and climate. A cross-sectional validation was con-
ducted. All consenting asthmatic patients aged 11 years
and above attending the Specialist Respiratory Clinic in
KK Women’s and Children’s Hospital participated.
Patients with other co-morbidities that could signiﬁcantly
affect their HRQoL were excluded. RESULTS: The
adapted CAQ-C was validated in 99 patients (41 females
and 58 males) with a mean age of 12.84 °Ó1.64 years
(range: 10–17 years). More than three quarters completed
the questionnaire in 10 minutes or less. The Severity (12
items), Distress (11 items) and Active Quality of Living
(4 items) scales had similar internal consistency as the UK
and Australian versions (Cronbach’s a = 0.71–0.85). Our
Teenage Quality of Living scale had only 3 items but
